NI201400110A - Tratamiento del cáncer con inhibidores tor cinasa - Google Patents
Tratamiento del cáncer con inhibidores tor cinasaInfo
- Publication number
- NI201400110A NI201400110A NI201400110A NI201400110A NI201400110A NI 201400110 A NI201400110 A NI 201400110A NI 201400110 A NI201400110 A NI 201400110A NI 201400110 A NI201400110 A NI 201400110A NI 201400110 A NI201400110 A NI 201400110A
- Authority
- NI
- Nicaragua
- Prior art keywords
- tor kinase
- kinase inhibitors
- cancer treatment
- prostate cancer
- resistant prostate
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 abstract 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261611428P | 2012-03-15 | 2012-03-15 | |
| US201261715327P | 2012-10-18 | 2012-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201400110A true NI201400110A (es) | 2015-01-12 |
Family
ID=48045717
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201400110A NI201400110A (es) | 2012-03-15 | 2014-09-12 | Tratamiento del cáncer con inhibidores tor cinasa |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20130245028A1 (enExample) |
| EP (1) | EP2825171B1 (enExample) |
| JP (2) | JP2015511964A (enExample) |
| KR (1) | KR102057357B1 (enExample) |
| CN (2) | CN109846884A (enExample) |
| AU (2) | AU2013202992B2 (enExample) |
| BR (1) | BR112014022700A2 (enExample) |
| CA (1) | CA2867174C (enExample) |
| EA (1) | EA028062B1 (enExample) |
| ES (1) | ES2668279T3 (enExample) |
| IL (1) | IL234639B (enExample) |
| MX (1) | MX359227B (enExample) |
| MY (1) | MY198666A (enExample) |
| NI (1) | NI201400110A (enExample) |
| NZ (1) | NZ628420A (enExample) |
| PH (1) | PH12014502047B1 (enExample) |
| SG (1) | SG11201405686PA (enExample) |
| TW (1) | TWI622395B (enExample) |
| UA (1) | UA114194C2 (enExample) |
| WO (1) | WO2013138560A1 (enExample) |
| ZA (1) | ZA201406708B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
| ES2638179T3 (es) | 2013-01-16 | 2017-10-19 | Signal Pharmaceuticals, Llc | Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos |
| WO2014172425A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Treatment of cancer with dihydropyrazino-pyrazines |
| US9474757B2 (en) | 2013-04-17 | 2016-10-25 | Signal Pharmaceuticals, Llc | Methods for treating cancer using TOR kinase inhibitor combination therapy |
| US9937169B2 (en) * | 2013-04-17 | 2018-04-10 | Signal Pharmaceuticals, Llc | Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy |
| MX374749B (es) | 2013-04-17 | 2025-03-06 | Signal Pharm Llc | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer. |
| HK1221150A1 (zh) | 2013-04-17 | 2017-05-26 | 西格诺药品有限公司 | 用二氢吡嗪并-吡嗪类对癌症的治疗 |
| SG11201508527VA (en) | 2013-04-17 | 2015-11-27 | Signal Pharm Llc | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one |
| KR20160002792A (ko) | 2013-04-17 | 2016-01-08 | 시그날 파마소티칼 엘엘씨 | 암 치료용 tor 키나제 억제제 및 n-(3-(5-플루오로-2-(4-(2-메톡시에톡시)페닐아미노)피리미딘-4-일아미노)페닐)아크릴아미드를 포함하는 병용 요법 |
| CA2912627C (en) | 2013-05-29 | 2022-03-15 | Signal Pharmaceuticals, Llc | Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use |
| NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
| JP2017514806A (ja) | 2014-04-16 | 2017-06-08 | シグナル ファーマシューティカルズ，エルエルシー | Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法 |
| US9512129B2 (en) | 2014-04-16 | 2016-12-06 | Signal Pharmaceuticals, Llc | Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer |
| NZ629796A (en) | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| CN106715427A (zh) | 2014-07-14 | 2017-05-24 | 西格诺药品有限公司 | 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法 |
| EP3313403A4 (en) * | 2015-06-24 | 2019-02-20 | Celgene Corporation | TREATMENT OF CANCER WITH DNAPK INHIBITORS |
| WO2017132235A1 (en) * | 2016-01-26 | 2017-08-03 | Dana-Farber Cancer Institute, Inc. | METHODS FOR TREATING BRAIN METASTASES USING COMBINATIONS OF ANTI-P13K AND ANTI-mTOR AGENTS |
| KR102795129B1 (ko) | 2017-06-22 | 2025-04-15 | 셀진 코포레이션 | B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009004019A (es) * | 2006-10-19 | 2009-06-19 | Signal Pharm Llc | Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa. |
| US7981893B2 (en) | 2006-10-19 | 2011-07-19 | Signal Pharmaceuticals, Llc | Heteroaryl compounds, compositions thereof, and methods of treatment therewith |
| KR101313486B1 (ko) * | 2008-07-10 | 2013-10-01 | 제이엑스 닛코 닛세키 킨조쿠 가부시키가이샤 | 하이브리드 실리콘 웨이퍼 및 그 제조 방법 |
| CA2734828C (en) * | 2008-08-20 | 2018-07-24 | J. Silvio Gutkind | Chemoprevention of head and neck squamous cell carcinomas |
| WO2010044893A1 (en) * | 2008-10-17 | 2010-04-22 | Merck & Co. | Combination therapy |
| US8110578B2 (en) * | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| US8420329B2 (en) * | 2008-11-20 | 2013-04-16 | Oncotherapy Science, Inc. | Methods for diagnosing or treating prostate cancer |
| CA2760778A1 (en) * | 2009-05-13 | 2010-11-18 | Amgen Inc. | Heteroaryl compounds as pikk inhibitors |
| KR20120091240A (ko) | 2009-10-26 | 2012-08-17 | 시그날 파마소티칼 엘엘씨 | 헤테로아릴 화합물의 합성 및 정제 방법 |
| AR078793A1 (es) * | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
-
2013
- 2013-03-14 US US13/803,317 patent/US20130245028A1/en not_active Abandoned
- 2013-03-14 CA CA2867174A patent/CA2867174C/en active Active
- 2013-03-14 SG SG11201405686PA patent/SG11201405686PA/en unknown
- 2013-03-14 MX MX2014011116A patent/MX359227B/es active IP Right Grant
- 2013-03-14 AU AU2013202992A patent/AU2013202992B2/en active Active
- 2013-03-14 EP EP13714092.7A patent/EP2825171B1/en active Active
- 2013-03-14 JP JP2015500599A patent/JP2015511964A/ja active Pending
- 2013-03-14 UA UAA201411214A patent/UA114194C2/uk unknown
- 2013-03-14 TW TW102109152A patent/TWI622395B/zh active
- 2013-03-14 KR KR1020147028708A patent/KR102057357B1/ko active Active
- 2013-03-14 BR BR112014022700-4A patent/BR112014022700A2/pt not_active Application Discontinuation
- 2013-03-14 EA EA201491701A patent/EA028062B1/ru not_active IP Right Cessation
- 2013-03-14 MY MYPI2014702599A patent/MY198666A/en unknown
- 2013-03-14 ES ES13714092.7T patent/ES2668279T3/es active Active
- 2013-03-14 NZ NZ628420A patent/NZ628420A/en unknown
- 2013-03-14 CN CN201910158858.3A patent/CN109846884A/zh active Pending
- 2013-03-14 CN CN201380024216.5A patent/CN104271138A/zh active Pending
- 2013-03-14 WO PCT/US2013/031217 patent/WO2013138560A1/en not_active Ceased
-
2014
- 2014-09-12 NI NI201400110A patent/NI201400110A/es unknown
- 2014-09-12 ZA ZA2014/06708A patent/ZA201406708B/en unknown
- 2014-09-14 IL IL234639A patent/IL234639B/en active IP Right Grant
- 2014-09-15 PH PH12014502047A patent/PH12014502047B1/en unknown
-
2015
- 2015-08-13 AU AU2015213353A patent/AU2015213353B2/en active Active
-
2017
- 2017-11-13 JP JP2017218388A patent/JP6470822B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201400110A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| NI201400109A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| MX373925B (es) | Tratamiento del cancer con inhibidores de tor cinasa. | |
| NI201400111A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| MX368286B (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer. | |
| NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
| MX2015014596A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto imid para tratar cancer. | |
| CR20120406A (es) | Identificación de mutación lkb1 como un biomarcador predictivo para sensibilidad a inhibidores de tor cinasa | |
| NI201500055A (es) | Tratamiento de cáncer de próstata con inhibidores de quinasa tor | |
| MX2013003076A (es) | Terapeuticos contra cancer de mama. | |
| MX374749B (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer. | |
| NI201500151A (es) | Terapia de combinación que comprende un compuesto de dihidropirazino-pirazina y un antagonista de receptor de andrógenos para tratar cáncer de próstata. | |
| UY35033A (es) | Formulación en comprimidos de un inhibidor de la fosfatidilinositol 3-cinasa | |
| CR20140480A (es) | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek | |
| EA201491695A1 (ru) | Лечение рака ингибиторами tor-киназы |